Seminars in Nephrology
Volume 29, Issue 4 , Pages 399-411 , July 2009

Hereditary Renal Tubular Disorders

  • Vimal Chadha, MD

      Affiliations

    • Section of Nephrology, Department of Pediatrics, Virginia Commonwealth University Medical Center, Richmond, VA
    • ,
  • Uri S. Alon, MD

      Affiliations

    • Section of Nephrology, Department of Pediatrics, The Children's Mercy Hospital and Clinics, University of Missouri at Kansas City, Kansas City, MO
    • Corresponding Author InformationAddress reprint requests to Uri S. Alon, MD, Pediatric Nephrology, The Children's Mercy Hospital and Clinics, 2401 Gillham Rd, Kansas City, MO 64108

References 

  1. Wrong OM, Norden AG, Feest TG. Dent's disease; a familial proximal renal tubular syndrome with low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease, progressive renal failure and a marked male predominance. Q J Med. 1994;87:473–493
  2. Frymoyer PA, Scheinman SJ, Dunham PB, Jones DB, Hueber P, Schroeder ET. X-linked recessive nephrolithiasis with renal failure. N Engl J Med. 1991;325:681–686
  3. Bolino A, Devoto M, Enia G, Zoccali C, Weissenbach J, Romeo G. Genetic mapping in the Xp11.2 region of a new form of X-linked hypophosphatemic rickets. Eur J Hum Genet. 1993;1:269–279
  4. Akuta N, Lloyd SE, Igarashi T, Shiraga H, Matsuyama T, Yokoro S, et al. Mutations of CLCN5 in Japanese children with idiopathic low molecular weight proteinuria, hypercalciuria and nephrocalcinosis. Kidney Int. 1997;52:911–916
  5. Igarashi T, Gunther W, Sekine T, Inatomi J, Shiraga H, Takahasha S, et al. Functional characterization of renal chloride channel, CLCN5, mutations associated with Dent'sJapan disease. Kidney Int. 1998;54:1850–1856
  6. Lloyd SE, Pearce SH, Fisher SE, Steinmeyer K, Schwappach B, Scheinman SJ, et al. A common molecular basis for three inherited kidney stone diseases. Nature. 1996;379:445–449
  7. Gunther W, Luchow A, Cluzeaud F, Vandewalle A, Jentsch TJ. CIC-5, the chloride channel mutated in Dent's disease, colocalizes with the proton pump in endocytotically active kidney cells. Proc Natl Acad Sci U S A. 1998;95:8075–8080
  8. Wang Y, Cai H, Cebotaru L, Hryciw DH, Weinman EJ, Donowitz M, et al. CIC-5: role in endocytosis in the proximal tubule. Am J Physiol Renal Physiol. 2005;289:F850–F862
  9. Christensen EI, Devuyst O, Dom G, Nielsen R, Van der Smissen P, Verroust P, et al. Loss of chloride channel C1C-5 impairs endocytosis by defective trafficking of megalin and cubilin in kidney proximal tubules. Proc Natl Acad Sci U S A. 2003;100:8472–8477
  10. Presley JF, Mayor S, McGraw TE, Dunn KW, Maxfield FR. Bafilomycin A1 treatment retards transferring receptor recycling more than bulk membrane recycling. J Biol Chem. 1997;272:13929–13936
  11. Picollo A, Pisch M. Chloride/proton antiporter activity of mammalian CLC proteins C1C-4 and C1C-5. Nature. 2005;436:420–423
  12. Moulin P, Igarashi T, Van der Smissen P, Cosyns JP, Verroust P, Thakker RV, et al. Altered polarity and expression of H+-ATPase without ultrastructural changes in kidneys of Dent's disease patients. Kidney Int. 2003;63:1285–1295
  13. Luyckx VA, Leclercq B, Dowland LK, Yu AS. Diet-dependent hypercalciuria in transgenic mice with reduced CLC5 chloride channel expression. Proc Natl Acad Sci U S A. 1999;96:12174–12179
  14. Carr G, Simmons NL, Sayer JA. Disruption of clc-5 leads to a redistribution of annexin A2 and promotes calcium crystal agglomeration in collecting duct epithelial cells. Cell Mol Life Sci. 2006;63:367–377
  15. Tosetto E, Ghiggeri GM, Emma F, Barbano G, Carrea A, Vezzoli G, et al. Phenotypic and genetic heterogeneity in Dent's disease—the results of an Italian collaborative study. Nephrol Dial Transplant. 2006;21:2452–2463
  16. Hoopes RR, Shrimpton AE, Knohl SJ, Hueber P, Hoppe B, Matyus J, et al. Dent disease with mutations in OCRL1. Am J Hum Genet. 2005;76:260–267
  17. Raja KA, Schurman S, D'mello RG, Blowey D, Goodyer P, Van Why S, et al. Responsiveness of hypercalciuria to thiazide in Dent's disease. J Am Soc Nephrol. 2002;13:2938–2944
  18. Cebotaru V, Kaul S, Devuyst O, Cai H, Racusen L, Guggino WB, et al. High citrate diet delays progression of renal insufficiency in the CIC-5 knockout mouse model of Dent's disease. Kidney Int. 2005;68:642–652
  19. Cutillas PR, Chalkley RJ, Hansen KC, Cramer R, Norden AG, Waterfield MD, et al. The urinary proteome in Fanconi syndrome implies specificity in the reabsorption of proteins by renal proximal tubule cells. Am J Physiol Renal Physiol. 2004;287:F353–F364
  20. Bartter FC, Pronove P, Gill JR, MacCardle RC. Hyperplasia of juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. Am J Med. 1962;33:811–828
  21. Seyberth HW, Rascher W, Schweer H, Kuhl PG, Mehls O, Scharer K. Congenital hypokalemia with hypercalciuria in preterm infants: a hyperprostaglandinuric tubular syndrome different from Bartter syndrome. J Pediatr. 1985;107:694–701
  22. Guay-Woodford L. Bartter syndrome: unraveling the pathophysiologic enigma. Am J Med. 1998;105:151–161
  23. Brennan TM, Landau D, Shalev H, Lamb F, Schutte BC, Walder RY, et al. Linkage of infantile Bartter syndrome with sensorineural deafness to chromosome lp. Am J Hum Genet. 1998;62:355–361
  24. Vargas-Poussou R, Huang C, Hulin P, Houillier P, Jeunemaitre X, Pailllard M, et al. Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J Am Soc Nephrol. 2002;13:2259–2266
  25. Watanabe S, Fukumoto S, Chang H, Takeuchi Y, Hasegawa Y, Okazaki R, et al. Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet. 2002;360:692–694
  26. Clive D. Bartter's syndrome: the unsolved puzzle. Am J Kidney Dis. 1995;25:813–823
  27. Simon DB, Karet FE, Hamdan JM, Dipietro A, Sanjad SA, Lifton RP. Bartter's syndrome, hypokalemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2C1 cotransporter NKCC2. Nat Genet. 1996;13:183–188
  28. International Collaborative Study Group for Bartter-Like Syndromes. Mutations in the gene encoding the inwardly rectifying renal potassium channel, ROMK, cause the antenatal variant of Bartter syndrome: evidence for genetic heterogeneity. Hum Mol Genet. 1997;6:17–26
  29. Ammenti A, Montali S. “Neonatal variant” of Bartter syndrome presenting with acidosis. Pediatr Nephrol. 1996;10:79–80
  30. Simon DB, Bindra RS, Mansfield TA, Nelson-Williams C, Mendonca E, Stone R, et al. Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. Nat Genet. 1997;17:171–178
  31. Estevez R, Boettger T, Stein V, Birkenhager R, Otto E, Hildebrandt F, et al. Barttin is a C1− channel beta-subunit crucial for renal C1− reabsorption and inner ear K+ secretion. Nature. 2001;414:558–561
  32. Birkenhager R, Otto E, Schurmann MJ, Vollmer M, Ruf EM, Maier-Lutz I, et al. Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet. 2001;29:310–314
  33. Jeck N, Reinalter SC, Henne T, Marg W, Mallmann R, Pasel K, et al. Hypokalemic salt-losing tubulopathy with chronic renal failure and sensorineural deafness. Pediatrics. 2001;108:E5
  34. Schlingmann KP, Konrad M, Jeck N, Waldegger P, Reinalter SC, Holder M, et al. Salt wasting and deafness resulting from mutations in two chloride channels. N Engl J Med. 2004;350:1314–1319
  35. Ellison DH. Divalent cation transport by the distal nephron: insights from Bartter's and Gitelman's syndromes. Am J Physiol. 2000;279:F616–F625
  36. Scheinman SJ, Guay-Woodford LM, Thakker RV, Warnock DG. Genetic disorders of renal electrolyte transport. N Engl J Med. 1999;340:1177–1187
  37. Calo L, Davis PA, Milani M, Cantaro S, Bonfante L, Favaro S, et al. Bartter's syndrome and Gitelman's syndrome: two entities sharing the same abnormality in vascular reactivity. Clin Nephrol. 1998;50:65–67
  38. Calo L, Davis PA, Milani M, Cantaro S, Antonello A, Favaro S, et al. Increased endothelial nitric oxide synthase mRNA level in Bartter's and Gitelman's syndrome (Relationship to vascular reactivity). Clin Nephrol. 1999;51:12–17
  39. Gitelman HJ, Graham JB, Welt LG. A new familial disorder characterized by hypokalemia and hypomagnesaemia. Trans Assoc Am Physicians. 1966;79:221–223
  40. Biner HL, Arpin-Bott MP, Loffing J, Wang X, Knepper M, Hebert SC, et al. Human cortical distal nephron: distribution of electrolyte and water transport pathways. J Am Soc Nephrol. 2002;13:836–847
  41. Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM, et al. Gitelman's variant of Bartter's syndrome, inherited hypokalemic alkalosis, is caused by mutations in the thiazide-sensitive Na-C1 cotransporter. Nat Genet. 1996;12:24–30
  42. Nijenhuis T, Vallon V, van der Kemp AW, Loffing J, Hoenderop JG, Bindels RJ. Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest. 2005;115:1651–1658
  43. Jeck N, Konrad M, Peters M, Weber S, Bonzel KE, Seyberth HW. Mutations in the chloride channel gene (CLCNKB, leading to a mixed Bartter-Gitelman phenotype). Pediatr Res. 2000;48:754–758
  44. Zelikovic I, Szargel R, Hawash A, Labay V, Hatib I, Cohen N, et al. A novel mutation in the chloride channel gene, CLCNKB, as a cause of Gitelman and Bartter syndromes. Kidney Int. 2003;63:24–32
  45. Seyberth HW. An improved terminology and classification of Bartter-like syndromes. Nat Clin Pract Nephrol. 2008;4:560–567
  46. Liddle GW, Bledsoe T, Coppage WS. A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans Am Assoc Physicians. 1963;76:199–213
  47. Lott JS, Coddington-Lawson SJ, Teesdale-Spittle PH, McDonald FJ. A single WW domain is the predominant mediator of the interaction between the human ubiquitin-protein ligase Nedd4 and the human epithelial sodium channel. Biochem J. 2002;361:481–488
  48. Chen SY, Bhargava A, Mastroberardino L, Meijer OC, Wang J, Buse P, et al. Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci U S A. 1999;96:2514–2519
  49. Pearce D, Verrey F, Chen SY, Mastroberardino L, Meijer OC, Wang J, et al. Role of SGK in mineralocorticoid-regulated sodium transport. Kidney Int. 2000;57:1283–1289
  50. Rossier BC, Pradervand S, Schild L, Hummler E. Epithelial sodium channel and the control of sodium balance: interaction between genetic and environmental factors. Annu Rev Physiol. 2002;64:877–897
  51. Tamura H, Schild L, Enomoto N, Matsui N, Marumo F, Rossier BC. Liddle disease caused by a missense mutation of beta subunit of the epithelial sodium channel gene. J Clin Invest. 1996;97:1780–1784
  52. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, et al. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell. 1994;79:407–414
  53. Schild L, Lu Y, Gautschi I, Schneeberger E, Lifton RP, Rossier BC. Identification of a PY motif in the epithelial Na channel subunits as a target sequence for mutations causing channel activation found in Liddle syndrome. EMBO J. 1996;15:2381–2387
  54. Staub O, Abriel H, Plant P, Ishikawa T, Kanelis V, Saleki R, et al. Regulation of the epithelial Na+ channel by Nedd4 and ubiquitination. Kidney Int. 2000;57:809–815
  55. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science. 2000;289:119–123
  56. New MI, Levine LS, Biglieri EG, Pareira J, Ulick S. Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension. J Clin Endocrinol Metab. 1997;44:924–933
  57. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 1988;242:583–585
  58. Hanukoglu A. Type I pseudohypoaldosteronism includes two clinically and genetically distinct entities with either renal or multiple target organ defects. J Clin Endocrinol Metab. 1991;73:936–944
  59. Rosler A, Theodor R, Gazit E, Biochis H, Rabinowitz D. Salt wasting, raised plasma-renin activity, and normal or high plasma aldosterone: a form of pseudohypoaldosteronism. Lancet. 1973;i:959–962
  60. Geller DS, Rodriguez-Soriano J, Vallo Boado A, Schifter S, Bayer M, Chang SS, et al. Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I. Nat Genet. 1998;19:279–281
  61. Chang S, Grunder S, Hanukoglu A, Rosler A, Matthew PM, Hanukoglu I, et al. Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalemic acidosis, pseudohypoaldosteronism type 1. Nat Genet. 1996;12:248–253
  62. Hanukoglu A, Bistritzer T, Rakover Y, Mandelberg A. Pseudohypoaldosteronism with increased sweat and saliva electrolyte values and frequent lower respiratory tract infections mimicking cystic fibrosis. J Pediatr. 1994;125:752–755
  63. Paver WK, Pauline GJ. Hypertension and hyperpotassaemia without renal disease in a young male. Med J Aust. 1964;35:305–306
  64. Schambelan M, Sebastian A, Rector FC. Mineralocorticoid-resistant renal hyperkalemia without salt wasting (type II pseudohypoaldosteronism): role of increased renal chloride reabsorption. Kidney Int. 1981;19:716–727
  65. Take C, Ikeda K, Kurasawa T, Kurokawa K. Increased chloride reabsorption as an inherited renal tubular defect in familial type II pseudohypoaldosteronism. N Engl J Med. 1991;324:472–476
  66. Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, et al. Human hypertension caused by mutations in WNK kinases. Science. 2001;293:1107–1112
  67. Kahle KT, Wilson FH, Lalioti M, Toka H, Qin H, Lifton RP. WNK kinases: molecular regulators of integrated epithelial ion transport. Curr Opin Nephrol Hypertens. 2004;13:557–562
  68. Kahle KT, Wilson FH, Leng Q, Lalioti MD, O'Connell AD, Dong K, et al. WNK4 regulates the balance between renal NaCl reabsorption and K+ secretion. Nat Genet. 2003;35:372–376
  69. Wilson FH, Kahle KT, Sabath E, Lalioti MD, Rapson AK, Hoover RS, et al. Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-C1 cotransporter is inhibited by wildtype but not mutant WNK4. Proc Natl Acad Sci U S A. 2003;100:680–684
  70. Yamauchi K, Rai T, Kobayashi K, Sohara E, Suzuki T, Itoh T, et al. Disease-causing mutant WNK4 increases paracellular chloride permeability and phosphorylates Claudine. Proc Natl Acad Sci U S A. 2004;101:4690–4694
  71. Agre P, Preston MG, Smith BL, Jung JS, Raina S, Moon C, et al. Aquaporin CHIP the archetypal molecular water channel. Am J Physiol Renal Fluid Electrolyte Physiol. 1993;265:F463–F476
  72. Nonoguchi H, Owada A, Kobayashi N, Takayama M, Terada Y, Koike J, et al. Immunohistochemical localization of V2 vasopressin receptor along the nephron and functional role of luminal V2 receptor in terminal inner medullary collecting ducts. J Clin Invest. 1995;96:1768–1778
  73. Kamsteeg EJ, Heijnen I, van Os CH, Deen PM. The subcellular localization of an aquaporin-2 tetramer depends on the stoichiometry of phosphorylated and nonphosphorylated monomers. J Cell Biol. 2000;151:919–930
  74. Nielsen S, Chou CL, Marples D, Christensen EI, Kishore BK, Knepper MA. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD-water channels to plasma membrane. Proc Natl Acad Sci U S A. 1995;92:1013–1017
  75. Bouley R, Hasler U, Lu H, Nunes P, Brown D. Bypassing vasopressin receptor signaling pathways in nephrogenic diabetes insipidus. Semin Nephrol. 2008;28:266–278
  76. Deen PM. Mouse models for congenital nephrogenic diabetes insipidus: what can we learn from them?. Nephrol Dial Transplant. 2007;22:1023–1026
  77. Cohen FE, Kelly JW. Therapeutic approaches to protein-misfolding diseases. Nature. 2003;426:905–909
  78. Bernier V, Morello J, Zarruk A, Debrand N, Salahpour A, Lonergan M, et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol. 2006;17:232–243
  79. Loonen A, Knoers N, van Os CH, Deen PM. Aquaporin 2 mutations in nephrogenic diabetes insipidus. Semin Nephrol. 2008;28:252–265
  80. Pattaragarn A, Alon US. Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor. Pediatr Nephrol. 2003;18:1073–1076
  81. Bichet DG. Vasopressin receptor mutations in nephrogenic diabetes insipidus. Semin Nephrol. 2008;28:245–251
  82. Yamamura Y, Ogawa H, Yamashita H, Chihara T, Miyamoto H, Nakamura S, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol. 1992;105:787–791
  83. Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007;67:847–858
  84. Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda Abedini M, et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med. 2005;352:1884–1890

 Supported in part by The Sam and Helen Kaplan Research Fund in Pediatric Nephrology.

PII: S0270-9295(09)00050-3

doi: 10.1016/j.semnephrol.2009.03.013

Seminars in Nephrology
Volume 29, Issue 4 , Pages 399-411 , July 2009

Article Tools

* Image Usage & Resolution